Dr. Daniel A. Pryma, MD
Nuclear Medicine (Nuclear Medicine Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 335
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nuclear Medicine Physician primary
PA license MD427361 -
Specialist
PA license MD427361
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 335
- Services billed
- 424
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Nuclear medicine study from skull base to mid-thigh with ct scan | 271 | 261 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 47 | 44 |
| Nuclear medicine study whole body with ct scan | 40 | 38 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 20 | 20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 18 | 18 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 15 | 15 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 13 | 13 |
| Nuclear medicine study of heart muscle blood flow by pet | 13 | 13 |
| Nuclear medicine study of bone and/or joint whole body | 12 | 12 |
| New patient office or other outpatient visit, 30-44 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $117 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $117 |
|---|
| Food and Beverage | $117 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $265,762 in research payments for these studies, mostly to the institutions running them.
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05477576 - A Phase 1 Study of (225Ac)-FPI-1434 Injection in Patients With Locally Advanced or Metastatic Solid Tumours
AstraZeneca Pharmaceuticals LP - INVFE
Progenics Pharmaceuticals, Inc. - Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
Eli Lilly and Company - A pivotal phase 2 trial of antibody naxitamab (HU3F8) and granulocyte-macrophage colony stimulating factor (gm-csf) in high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage…
Y-mabs Therapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.